Evidence map›Paper›PMID 42512323›Full record

ArticleCancers2026

Interplay Between Immune Checkpoint Modulators and the Epithelial-to-Mesenchymal Transition Axis in Clear Cell Renal Cell Carcinoma.

Arpita Poddar, Farah Ahmady-Nield, Revati Sharma, Seemadri Subhadarshini, Mohit Kumar Jolly, Suresh Ramakrishna, Ali Raza, Ravi Shukla, George Kannourakis, Aparna Jayachandran and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Arpita PoddarFiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.
Farah Ahmady-NieldFiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.
Revati SharmaFiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.
Seemadri SubhadarshiniDepartment of Bioengineering, Indian Institute of Science, Bengaluru 560012, Karnataka, India.
Mohit Kumar JollyDepartment of Bioengineering, Indian Institute of Science, Bengaluru 560012, Karnataka, India.ORCID 0000-0002-6631-2109
Suresh RamakrishnaGraduate School of Biomedical Science and Engineering, Hanyang University, Seoul 04763, Republic of Korea.
Ali RazaFiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.
Ravi ShuklaIan Potter NanoBiosensing Facility, NanoBiotechnology Research Laboratory, School of Science, RMIT University, Melbourne, VIC 3000, Australia.ORCID 0000-0002-1537-9637
George KannourakisFiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.ORCID 0000-0001-6880-9795
Aparna JayachandranFiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.
Prashanth PrithvirajFiona Elsey Cancer Research Institute, Ballarat, VIC 3350, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AUCbiomarkersclear cell renal cell carcinomaepithelial-to-mesenchymal transitionimmune checkpoint inhibitorsLAG3NT5EPD-L1single-cell RNA sequencingsurvival

Identifiers

PMID42512323
PMCPMC13406277

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.